Nakamura T, Okumura M, Takamune N, Hirotsu T, Sugiura M, Yasunaga J
PNAS Nexus. 2024; 3(1):pgad446.
PMID: 38170115
PMC: 10758923.
DOI: 10.1093/pnasnexus/pgad446.
Wang H, Ikwuagwu J, Tran V, Tran N
J HIV Ageing. 2023; 7(2):29-36.
PMID: 36714525
PMC: 9879272.
DOI: 10.19198/jha31533.
Wiesner A, Skronska M, Gawlik G, Marcinkowska M, Zagrodzki P, Pasko P
AIDS Behav. 2022; 27(5):1441-1468.
PMID: 36318429
PMC: 10129904.
DOI: 10.1007/s10461-022-03880-6.
Lu C, Bednarczyk E, Catanzaro L, Shon A, Xu J, Ma Q
Curr Res Pharmacol Drug Discov. 2021; 2:100044.
PMID: 34909672
PMC: 8663927.
DOI: 10.1016/j.crphar.2021.100044.
Bukkems V, Post T, Colbers A, Burger D, Svensson E
CPT Pharmacometrics Syst Pharmacol. 2020; 10(2):161-172.
PMID: 33369217
PMC: 7894397.
DOI: 10.1002/psp4.12586.
Low raltegravir transfer into the breastmilk of a woman living with HIV.
Feiterna-Sperling C, Bukkems V, Teulen M, Colbers A
AIDS. 2020; 34(12):1863-1865.
PMID: 32675580
PMC: 8635245.
DOI: 10.1097/QAD.0000000000002624.
Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review.
Podany A, Scarsi K, Pham M, Fletcher C
Clin Pharmacokinet. 2020; 59(9):1085-1107.
PMID: 32462541
PMC: 7484053.
DOI: 10.1007/s40262-020-00898-8.
Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling.
Liu X, Momper J, Rakhmanina N, Green D, Burckart G, Cressey T
Clin Pharmacokinet. 2020; 59(11):1433-1450.
PMID: 32451908
PMC: 7666002.
DOI: 10.1007/s40262-020-00897-9.
Effect of a High-Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir.
Patel P, Ford S, Lou Y, Bakshi K, Tenorio A, Zhang Z
Clin Pharmacol Drug Dev. 2018; 8(4):443-448.
PMID: 30230694
PMC: 6585996.
DOI: 10.1002/cpdd.620.
Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.
Podany A, Scarsi K, Fletcher C
Clin Pharmacokinet. 2016; 56(1):25-40.
PMID: 27317415
PMC: 5164870.
DOI: 10.1007/s40262-016-0424-1.
Pharmacokinetic determinants of virological response to raltegravir in the in vitro pharmacodynamic hollow-fiber infection model system.
Brown A, Adams J, Baluya D, Drusano G
Antimicrob Agents Chemother. 2015; 59(7):3771-7.
PMID: 25870053
PMC: 4468687.
DOI: 10.1128/AAC.00469-15.
Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age.
Rizk M, Du L, Bennetto-Hood C, Wenning L, Teppler H, Homony B
J Clin Pharmacol. 2015; 55(7):748-56.
PMID: 25753401
PMC: 4572519.
DOI: 10.1002/jcph.493.
Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.
Weiner M, Egelund E, Engle M, Kiser M, Prihoda T, Gelfond J
J Antimicrob Chemother. 2013; 69(4):1079-85.
PMID: 24343893
PMC: 4014856.
DOI: 10.1093/jac/dkt483.
Divalent metals and pH alter raltegravir disposition in vitro.
Moss D, Siccardi M, Murphy M, Piperakis M, Khoo S, Back D
Antimicrob Agents Chemother. 2012; 56(6):3020-6.
PMID: 22450971
PMC: 3370743.
DOI: 10.1128/AAC.06407-11.
Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients.
Rizk M, Hang Y, Luo W, Su J, Zhao J, Campbell H
Antimicrob Agents Chemother. 2012; 56(6):3101-6.
PMID: 22430964
PMC: 3370742.
DOI: 10.1128/AAC.06417-11.
Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection.
Sandkovsky U, Swindells S, Moore R, Acosta E, Fletcher C
Pharmacotherapy. 2012; 32(2):142-7.
PMID: 22392423
PMC: 3711779.
DOI: 10.1002/PHAR.1015.
Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.
Pandey K
Clin Med Rev Ther. 2012; 2012(4):13-30.
PMID: 22389581
PMC: 3289997.
DOI: 10.4137/CMRT.S5022.
Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.
Arab-Alameddine M, Fayet-Mello A, Lubomirov R, Neely M, di Iulio J, Owen A
Antimicrob Agents Chemother. 2012; 56(6):2959-66.
PMID: 22371894
PMC: 3370715.
DOI: 10.1128/AAC.05424-11.
Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir.
Song I, Borland J, Chen S, Patel P, Wajima T, Peppercorn A
Antimicrob Agents Chemother. 2011; 56(3):1627-9.
PMID: 22183173
PMC: 3294934.
DOI: 10.1128/AAC.05739-11.
